Treatment Information

Back

Kidney (Renal) Cancer treatment details. Chemotherapy, Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, NY
Treatments:Chemotherapy, Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Sep 2007

Description:

Patients: This phase I/II study involved seventy-one patients with stage IV renal cell carcinoma. Of these patients, 39 (55%) had prior therapy. The majority of patients (76%) were men, and the median age was 59, ranging from 35 to 80 years old.

Treatment: Patients were treated with the biological therapy interferon –alpha and then the chemotherapy drug temsirolimus.

Toxicity: The most common grade 3 and 4 events included leukopenia, asthenia, hypophosphatemia, anemia, and hypertriglyceridemia. One patient experienced grade 3 interstitial pneumonia. Adverse events leading to treatment with lower doses of temsirolimus occurred in 55% of the patients.

Results: The median overall survival of all patients was 18.8 months. Not all patients were treated with the same number of doses or amount of drugs; for patients that received the ‘recommended-dose’ the median overall survival was 22.1 months

Support: This study was supported by Wyeth, which makes and/or markets temsirolimus.

Correspondence: Dr. Robert J. Motzer





Back